Keywords: InterMune, Esbriet, FDA, Additional trial, Shire, Vyvanse, IPF, ADHD

InterMune plunges as US FDA calls for additional testing of IPF drug Esbriet; agency clears label change for Shire’s Vyvanse

Article | 05 May 2010

Print This

InterMune saw a melt-down in its share price, after it revealed that the US Food and Drug Administration had issued ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in